MIM
TRVI icon

MetLife Investment Management’s Trevi Therapeutics TRVI Stock Holding History

MetLife Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
62,493
+10,679
+21% +$155K 0.01% 1445
2026
Q1 		$618K Buy
51,814
+1,564
+3% +$17.5K ﹤0.01% 1648
2025
Q4 		$629K Sell
50,250
-502
-1% -$5.8K ﹤0.01% 1683
2025
Q3 		$464K Buy
50,752
+6,096
+14% +$45.7K ﹤0.01% 1843
2025
Q2 		$244K Hold
44,656
– – ﹤0.01% 2084
2025
Q1 		$281K Buy
44,656
+5,871
+15% +$28K ﹤0.01% 2009
2024
Q4 		$160K Buy
38,785
+19,857
+105% +$63.6K ﹤0.01% 2414
2024
Q3 		$63.2K Buy
18,928
+47
+0.2% +$140 ﹤0.01% 2729
2024
Q2 		$56.3K Sell
18,881
-3,812
-17% -$10.6K ﹤0.01% 2739
2024
Q1 		$78.3K Buy
+22,693
New +$50.6K ﹤0.01% 2641

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

MetLife Investment Management's TRVI Position: Q2 2026 in Review

MetLife Investment Management increased its Trevi Therapeutics (TRVI) stake by 21% in Q2 2026, buying an estimated $155K and bringing the position to 62,493 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #1445.

MetLife Investment Management first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • MetLife Investment Management held 62,493 shares of Trevi Therapeutics worth $1.17M as of Q2 2026.
  • MetLife Investment Management bought 10,679 Trevi Therapeutics shares in Q2 2026, an estimated $155K.
  • Trevi Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1445 holding.
  • MetLife Investment Management first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.